Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 2Ovarian Cancer Recurrent 2Fallopian Tube Neoplasms 2Stomach Neoplasms 1Platinum-resistant Recurrent Ovarian Cancer 1Platinum-resistant Ovarian Cancer 1

Interventions

Oxaliplatin 42Fluorouracil 27Capecitabine 24pembrolizumab 21S 1 (combination) 19Paclitaxel 19Leucovorin 16Nivolumab 13Docetaxel 13sintilimab 12Drug Therapy 12tislelizumab 10Trastuzumab 10Cisplatin 10Irinotecan 9Bevacizumab 8trastuzumab deruxtecan 7spartalizumab 7XELOX 7Surgical Procedures, Operative 7Radiotherapy 7Hyperthermic Intraperitoneal Chemotherapy 7Biopsy 7fludarabine 6disitamab vedotin 6Cyclophosphamide 6lenvatinib 5apatinib 5Specimen Handling 5Ramucirumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Stomach Neoplasms × 1-dodecylpyridoxal × Clear all
NCT05536102 2023-03-09

The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡